In 2012, RAND Europe and the Health Economics Research Group (Brunel University) were commissioned by the Wellcome Trust, Cancer Research UK, the National Institute for Health Research and the Academy of Medical Science to conduct a study of the returns to the public/charitable investment in cancer-related research. This study built on previous work published in the 2008 'What's it worth?' report that estimated the economic returns to medical research in terms of spillover benefits and health gain. The 2008 study was extensively quoted and cited as a clear justification for the economic importance of medical research and appears to have played a role in achieving the protection of the medical science budget in the recent public expenditure cuts.
This cancer study used a similar approach to that used in the previous study, but with some methodological developments. One of the methodological developments was the inclusion of case studies to examine the validity and variability of the estimates on elapsed time between funding and health gains, and the amount of health gains that can be attributed to UK research. This report provides the full text of the five case studies conducted as well as some discussion of observations emerging across the case study set.
Table of Contents
Case study 1: The use of guaiac-based faecal occult blood test in bowel cancer screening
Case Study 2: Service configuration
Case study 3: Smoking reduction
Case study 4: The use of tamoxifen in the treatment of breast cancer
Case study 5: Total mesorectal excision (TME) in rectal cancer
Discussion and observations